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Abstract
Objective: This article aims to review the comorbidity of premenstrual syndrome (PMS) or 
premenstrual dysphoric disorder (PMDD) and bipolar disorder (BD), identify variables requiring 
further investigation and to remind physicians that special care is required for diagnosis and 
therapy. Method: A systematic review of articles published from 1987 to February 2012 was 
conducted in the Medline database with the following terms: (premenstrual syndrome OR 
premenstrual dysphoric disorder OR premenstrual) AND (bipolar OR mania OR manic). Seventeen 
articles were analyzed. Results: PMS and PMDD were most often comorbid among BD-II patients 
and vice versa. Moreover, patients with PMS or PMDD also have an increased risk of having BD-I. 
In addition, bipolar women susceptible to hormonal changes exhibit more severe symptoms, more 
frequent relapses and a worse therapeutic response. Conclusion: Future investigations should 
attempt to stabilize hormonal levels through the continuous use of contraceptives to target a 
reduction in symptom severity. In addition, psychiatrists should note menstrual period dates and 
compare symptom intensity between the luteal and follicular phases. Finally, PMS and PMDD 
patients should be studied separately.
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Comorbidade entre o Transtorno Bipolar e Síndrome Pré-Menstrual ou Transtorno 
Disfórico Pré-menstrual: uma revisão sistemática
Resumo
Objetivo: Esse artigo tem como objetivo revisar a comorbidade entre a Síndrome Pré-Menstrual 
(SPM) ou Transtorno Disfórico Pré-Menstrual (TDPM)
variáveis que exigem uma investigação mais aprofundada e lembrar os médicos que as mulheres 
necessitam de cuidados especiais para diagnóstico e tratamento. Método: Foi realizada uma 
revisão sistemática de 1987 a fevereiro de 2012 através da base de dados Medline utilizando 
os seguintes descritores: (premenstrual syndrome OR premenstrual dysphoric disorder OR 
premenstrual) AND (bipolar OR mania OR manic). Dezessete artigos foram analisados. Resultados: 
Pacientes com SPM ou TDPM possuem comorbidade com TB-II com maior frequência e vice-versa. 
Mulheres com SPM ou TDPM também possuem um risco aumentado apresentar TB-I. Além disso, 
as mulheres bipolares suscetíveis a mudanças hormonais cursam com sintomas mais graves, 
recaídas mais freqüentes e pior resposta terapêutica. Conclusão: Futuras investigações devem 
estabilizar os níveis hormonais com o uso contínuo de contraceptivos na tentativa de diminuir 
a gravidade dos sintomas. Além disso, psiquiatras devem observar os períodos menstruais e 
comparar a intensidade dos sintomas entre as fases folicular e lútea. Pacientes com SPM ou 
TDPM devem ser estudadas separadamente.
DESCRITORES:
Transtorno Bipolar;
Estrógenos;
Síndrome Pré-Menstrual;
Progesterona;
Serotonina.
Introduction
 
and its estimated prevalence ranges from 75% to 95%.1,5 
Premenstrual Dysphoric Disorder (PMDD) is the most severe 
form of PMS with more restrictive criteria and a predomi-
nance of emotional and behavioral symptoms. PMDD requires 
Appendix B (Criteria Sets and Axes Provided for Further 
Study).6 Only one of the 11 criteria is related to physical 
symptoms (Table 2). In contrast with PMS, PMDD affects only 
3 to 9% of women.7,8 The DSM-5 project included the PMDD 
criteria in the Depressive Disorders chapter.9 
Previous studies have focused on the lifetime comorbid-
ity of mood disorders,10 14 anxiety disorders15,17 and personality 
disorders18 in women with PMS (PMS+) or PMDD (PMDD+). 
Compared to women at other phases of their menstrual 
cycle, those in the premenstrual period present higher rates 
of hospitalization,15 emergency treatment17,19,21 and suicide 
attempts.16,17,20,22,24 Due to these regular relapses reported 
during the premenstrual phase, women may have a more 
severe expression and evolution of psychiatric disorders. 
Considering the gender differences in mood disorders, it is 
remarkable that BD women have a higher risk of postpartum 
mood episodes and pre-menopause.25,26 Mood disorders have 
the same prevalence prior to puberty.27 When the increase in 
sex hormones becomes evident, the female-to-male ratio of 
unipolar depression shifts to 2:1.28,29 Therefore, it is possible 
that steroid hormones might be involved. However, in rela-
tion to Bipolar Depression, the polarity of previous episodes 
is a controversial issue. Some researchers found that women 
have more depressive episodes than men,28,30 but others 
found no difference.31,32 Researchers have been studying 
the relationship between neurotransmitters, female gonadal 
hormones and the emergence and pattern of symptoms of 
premenstrual dysphoria.33,35 
Women with bipolar disorder have a higher risk of post-
partum mood episodes. At the same time, women with PMDD 
are more likely to experience mood disorders. Estrogen and 
modulate affective symptoms through their actions in the CNS.
It has been demonstrated that estrogen has a profound 
impact on mood and on the trimonoaminergic neurotransmit-
ter system (5HT, NE, and DA),36 GABA and glutamate, which 
are involved in the pathophysiology of depression.37 Estrogen 
decreases MAO activity, thus increasing 5-HT availability 
with a resulting antidepressant effect, whereas progester-
one increases MAO, which decreases 5-HT availability and 
depresses mood.38
It is currently accepted that women with premenstrual 
complaints differ from controls not with respect to ovarian 
function, but with respect to how responsive the target 
possible that women with PMS have an altered sensitivity 
to testosterone, as well as to progesterone and estrogen.
The association of PMS with axis I comorbidity and its 
mechanism was extensively studied in the latter part of 
the twentieth century, and there has been a resurgence 
of publications on this topic since 2007. Many researchers have 
patients, however the results vary.39,41 Among other subjects, 
Kim et al. reports the occurrence of PMS/PMDD and BD in two 
review articles.42,43 In the present review, PMS/PMDD and BD 
comorbidity is the central topic because the most accepted 
hypothesis is that this subgroup of women may be predisposed 
44
The aim of this article is to evaluate the comorbidity of 
PMS or PMDD with Bipolar Disorder (BD), to identify variables 
requiring further investigation and to remind physicians that 
special care is required for diagnosis and therapy. Therefore, 
BD and PMS/PMDD.
469BP and PMS or PMDD comorbidity: a systematic review
Table 1 Diagnostic Criteria for PMS (ACOG)10
A. Symptoms must occur during the 5 days before menses for at least 
3 menstrual cycles in a row. At least one affective and one somatic 
symptom must be present.
Affective Symptoms Somatic Symptoms
Depression Breast tenderness
Angry-outbursts Abdominal bloating
Irritability Headache
Anxiety Swelling of extremities
Confusion
Social withdrawal
B. Symptoms are relieved within 4 days without recurrence until cycle day 13
C. Symptoms are present in the absence of medicine, hormone ingestion 
or alcohol use
D. Symptoms occur during 2 cycles prospectively
E. Patient suffer social or economic dysfunction
ACOG: American College of Obstetricians and Gynecologists
Table 2 *6
A. Symptoms must occur during the week before menses, improve several 
days after the onset of menses and remit for up to 7 days.
Five or more of the following symptoms must be present, and at least 
one must be (1), (2), (3), or (4):
 1. Depressed mood or hopelessness
 2. Anxiety or tension
 3. Affective lability
 4. Irritability or anger
 5. Decreased interest in usual activities
 7. Marked lack of energy
 8. Marked change in appetite, overeating, or food cravings
 9. Hypersomnia or insomnia
 10. Feeling overwhelmed or out of control
 11. Other physical symptoms i.e., breast tenderness, bloating
B. Symptoms must interfere with work, school, usual social activities
 or relationships.
C. Symptoms are not merely an exacerbation of another disorder.
for at least two consecutive symptomatic cycles.
*Summarized.
Methods
Search strategy and eligibility criteria 
The search strategy aimed to gather as many studies as pos-
sible on the issue. Epidemiological, clinical and therapeutic 
data were all collected. To achieve this goal, we used the 
following search terms in the Medline database: (premen-
strual syndrome OR premenstrual dysphoric disorder OR 
premenstrual) AND (bipolar OR mania OR manic). The search 
was limited to studies from 1987, the year that the DSM-III-R 
included the criteria for late luteal phase dysphoric disor-
der (LLPDD), to February 2012. The name was changed to 
 
having almost identical criteria to those of LLPDD (only 1 item 
was added). Articles were included based on the following 
criteria: (1) type of study (original article or case report) and 
(2) language (English, Spanish or Portuguese). If more than 
one article referred to the same study, the article with the 
shorter follow-up was excluded. We further examined 
the reference lists of the included articles in an effort to 
excluded articles that did not separately evaluated bipolar 
was made by consensus. 
Results
searches. We excluded 14 articles because they were reviews, 
12 were published before the DSM-III-R (1987), one was in 
potentially relevant according to our criteria. 
Studies characteristics 
Nine studies evaluated the comorbidity of BD and PMS, 4 
studies assessed the comorbidity of BD and PMDD (one used 
the LLPDD criteria and was included in the PMDD group), and 
one evaluated both.45 
Prevalence 
Eight studies determined the PMS/PMDD prevalence in BD 
patients, four of which investigated PMDD and BD, including 
one that evaluated PMS and PMDD.
In relation to PMDD, Choi et al.45 examined its prevalence 
in 183 age-matched women (30 BD-I vs. 31 BD-II vs. 122 
healthy controls), and PMDD was present in 6.7% of patients 
with BD-I, 22.6% of those with BD-II, and in 1.6% of controls.45 
This study found that patients with BD-II disorder had statisti-
 
(p < 0.0001, 95% CI-NI).45 Choi et al.45 also evaluated the prev-
alence of “moderate to severe PMS,” and a trend of distinc-
tion was found between the BD-I and BD-II groups (p = 0.069) 
as well as a difference between BD-II patients and controls 
(p = 0.003).45 These results should be interpreted with caution 
because the analysis did not consider the pharmacological 
treatment status. As we know, BP-I patients may be more 
likely to receive treatment than BP-II patients, which might 
suppress the PMDD symptoms. Therefore, the pharmacologi-
cal treatment status is a potential confounder.
Wittchen et al.46 evaluated mental disorder co-morbidity 
and PMDD in a community sample (N = 1,251) of women be-
tween 14-24 years old in a 12-months follow-up.46 Regarding 
PMDD and bipolar disorder, they found that among sub-
threshold PMDD patients (n = 201), 3.8% were BDI (OR: 5.3, 
p < 0.05, 95% CI-NI) and 0.3% BDII (OR: 0.5) (46). Among the 
PMDD patients (n = 74), 5.7% were BDI (OR: 7.9, p < 0.01, 
95% CI-NI) and 4.9% were BDII (OR: 8.1, p < 0.01, 95% CI-NI), 
while in the PMDD - group (n = 828), 0.8% were BDI and 0.6% 
were BDII.46 Wittchen et al.46 found substantial co-morbidity 
between PMDD+ and BD-I and BD-II patients (approximately 
10%), particularly because the study was conducted with a 
large community sample.
Hardoy et al.47 compared the prevalence of PMDD in three 
diagnostic groups to 13 patients out of 17 (76.5%) with BD, 
9 patients out of 14 (64.3%) with MDD, and 6 patients out of 
16 (37.5%) controls.47 The proportion of women with PMDD 
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Table 3 Bipolar disorder (BD) and premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) comorbidity 
articles results
Author Year Sample/N Symptoms/Criteria Results
Dias et al.55 2011 191 with PME of BD and 102 
without
Number of premenstrual symptoms
Number of mood episodes overall
Number of depressive episodes
Number of manic or hippomanic episodes
Median time to relapse
Prevalence of rapid cycling
Greater in women with PME
Greater in women with PMS
Greater in women with PMS
No difference
Lower in PMS group
No difference
Choi et al.45 2010 30 BDI,31 BDII and 61 healthy 
controls
Prevalence of PMDD 
Prevalence of moderate to severe PMS 
PMS effect on the GSS scale 
Association of seasonality and PMS (BDI/BDII) 
Higher in BDII
Higher in BDII
No interaction
Stronger in BD group
Fornaro et al.48 2010 92 female outpatients and 
Inpatients BDI and BDII
Prevalence of PMDD 
Educational level 
Marital status
Mean age at onset of mood disorder
Rates of BDII and cyclothymia
Rates of BDI
Prevalence of post-partum depression
Mean age at the moment of the evaluation
Rapid cycling
Seasonal pattern
Psychotic features
Melancholia
Past hospitalization
Past suicidality
Carbohydrate craving
Scale score (CGI, YMRS)
Axis I comorbidity
Total mean number of comorbid conditions
Early in BD with PMS
Women with PMS were younger
No difference
No difference
No difference
No difference
No difference
No difference
No difference
Payne et al.50 2009 665 BD I, 1746 MDD Mean age at onset of mood disorder 
Age at interview 
Married prevalence 
Depression at the time of interview
Number of past depressive or manic episodes
History of pregnancy
Longest MDE (weeks)
Years educated
Family analyses for premenstrual mood 
symptoms
Early in BD with PMS
Women with PMS were younger
No difference
No difference
No difference
No difference
No difference
No difference
No difference
Payne et al.49 2007 665 BDI disorder, 112 BDII Prevalence of PMS
Associations between premenstrual and 
postpartum mood symptoms in women with a 
previous pregnancy
Association of depressed stated at the time of 
the interview with reproductive  
cycle-associated mood symptoms
No difference
No associations
More premenstrual and perimenopausal 
symptoms in BDI women depressed at 
the time of the interview
Hsiao et al.83 2007 6 case reports, 2 with BD  
and PMS
24-year-old woman with manic episodes  
2-3 days before menstruation
34-year-old woman with delusions and 
hallucinations one week before menstruation
Premenstrual doses of an antipsychotic
Mood stabilizer and antipsychotic doses 
were increased during the luteal phase
Hardoy et al.47 2006 4 BD I, 13 BDII, 14 MDD  
and 16 controls
Prevalence of PMDD in the three groups 
Prevalence of PMDD in mood vs. controls 
Plasma concentration of steroids 
Correlation between PD, OCD or ED  
comorbidity and steroids concentrations
No difference
higher in PMDD+
No association
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Table 3 Bipolar disorder (BD) and premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) comorbidity 
articles results (cont.)
Author Year Sample/N Symptoms/Criteria Results
Becker et al.78 2004 Case report 43 years-old woman with 30 years history of 
treatment-resistant rapid cycling bipolar II 
disorder with follicular phase depressive and 
luteal phase mood elevation symptoms
Complain about the premenstrual symptom 
PAF scores 
 
premenstrual symptom change of DRSP
Lamotrigine 300 mg/day, divalproex 
sodium 500 mg/day and levothyroxine 
175 lg/day
More in controls
Controls had higher scores in some 
items
BD with treatment-responsive had less 
Wittchen et al.46 2002 201 subthreshold PMDD
74 PMDD+
828 PMDD
BD-I and II prevalence
BD-I and II prevalence
Higher prevalence only for BD-I
Higher prevalence for both
Angst et al.52 2001 141 peri-MS+ and 106 controls BD prevalence Higher in peri-MS+
Gregory et al.53 2000 Eight of the 72 subjects with 
MDE were BD
Mood at four different reproductive cycle  
events (premenstrual, use of oral  
contraceptives, postpartum and  
perimenopausal)
Family history of BD 
Women with severe depression in two 
or more of them were more likely to 
have BD
No difference
Blehar et al.51 1998 186 BDI Prevalence of regular mood changes in 
premenstrual or menstrual phase
Primary symptoms as increased irritability, anger 
outbursts and mood lability versus depression 
High prevalence
Most patients felt irritability, anger and 
mood lability
Parry et al.57 1996 15 LLPDD+ women and  
15 controls
Prevalence of hypomania
Years of education
Higher in LLPDD+
No difference
Jacobsen77 1993 16 rapid cycling BDII 
outpatients,
11 of them with PMS
Response to low-dose valproate treatment 
Sustained response to valproate
Most PMS+ patients needed high doses
BDII women with primary PMS are less 
responsive
D’Mello et al.87 1993 2 case reports 29 years-old woman with premenstrual mania 
5 days before menses and euthymic during 
intermenstrual period
41-year-old with premenstrual mixed mania  
and stable mood between menses
lithium and thiothixene and maintained 
only with lithium (1,800 mg/day - 
serum D’Mello et level = 0.9 mEq/L)
lithium 900 mg/day with serum levels 
in the 0.6 to 0.8 mEq/L range
McMillan et al.58 1989 16 euthymic patients with 
affective disorder, only 4 BD Scale score (DRS, MAACL, HRS)
No difference
premenstrual depression with the 
scales
BD: bipolar disorder; BDI: bipolar disorder I; BDII: bipolar disorder II; BDD: Body Dysmorphic Disorder; CGI: Clinical Global Impression Scale; DRS: Daily 
Rating Scale; DRSP: Daily Record of Severity of Problems-Short Form; ED: eating disorder; GSS: Global Seasonality Score; HRS: Hamilton Rating Scale; 
MAACL: Multiple Affect Adjective Checklist; MDE: major depressive episode; OCD: Obsessive-compulsive Disorder; PAF: Premenstrual Assessment Form;  
PD: panic disorder; peri-MS+: with perimenstrual symptoms; PMDD: premenstrual dysphoric disorder; PMDD+: with premenstrual dysphoric disorder;  
PMDD-: without premenstrual dysphoric disorder; PME: premenstrual exacerbation; PMS: premenstrual syndrome; PMS+: with premenstrual syndrome;  
PMS-: without premenstrual syndrome; THPROG: allopregnanolone; YMRS: Young Mania Rating Scale.
 
p = 0.068).47 However, if all patients with mood disorders 
were grouped together, the difference compared with 
most likely due to the small sample size.47 The sample size 
increases when the two mood disorders groups are joined, 
and consequently, the power of the analysis reaches 
and II patients and detected 25 (27.2%) patients with a 
48 
Three of these patients (12.0%) had BD-I, while 22 (88.0%) 
had BD-II.48 In addition, PMDD+ was associated with higher 
rates of cyclothymia and BD-II than PMDD- (72% versus 36% 
and 88% versus 60%, respectively). On the other hand, BDI 
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was more frequent among PMDD- patients compared to 
PMDD + patients (40% versus 12%). It should be highlighted 
that PMDD is more frequent among patients with BD-II or 
cyclothymia than BD-I. The authors also found that the 
total mean number of comorbid conditions was greater in 
BD patients with PMDD+.48 Nevertheless, Fornaro and Perugi 
did not a rigorously distinguish among PMDD cases within 
different menstrual phases.
Regarding the studies that evaluated PMS, in 2007 
Payne et al.49 examined the prevalences of premenstrual 
mood symptoms in BD-I and BD-II patients, which were 
65.1% (433 of 665) and 70.5% (79 of 112), respectively.49 Two 
years later, Payne et al. evaluated 435 BD-I patients, the 
majority of whom had PMS (64.1%).50 Blehar assessed only 
BD-I women, and 66.1% (119/180) of them reported regular 
mood changes during the menstrual or premenstrual phase.51 
Angst et al.52 assessed seven psychological symptoms for 
the perimenstrual period in a community cohort study and 
found comorbidity with psychiatric syndromes.52 They found 
that the prevalence of BD was 9% among the 106 controls, 
17% among the 88 depressed peri-MS and 15% among non-
depressed peri-MS women (p all = 0.27).52 
In summary, eight studies assessed the prevalence of 
PMS/PMDD in BD patients. Two of them found a greater 
prevalence of PMS/PMDD in BD-II.45,48 Payne et al.50 and 
Blehar et al.51 only evaluated BD-I, but they found a high 
prevalence of PMS.50,51 Hardoy did not separate BD-I from 
BD-II and found no difference in the prevalence of PMDD in 
BD patients when compared to MDD patients or controls. 
However, we should emphasize the small sample size.47 
Wittchen et al. compared the prevalences of BD-I and BD-
II in subthreshold PMDD+, PMDD+ and PMDD- samples and 
in the subthreshold PMDD+ group only with BD-I.46
Reproductive cycle-related mood symptoms
One article described associations between post-partum de-
pression and PMDD+ BD-I and BD-II patients (PMDD+: 36.0% vs. 
PMDD-: 14.9%, p = 0.026).48 Another study examined whether 
premenstrual mood symptoms could predict postpartum 
mood symptoms in 517 women with BD-I with a previous 
pregnancy and found that the result was not statistically 
49 The diffeårence between the two 
Payne evaluated only BD-I patients and PMS while Fornaro 
and Perugi described PMDD in BD-I and BD-II.48,49
Payne et al. also used a sample of 197 women with BD-I 
who had undergone both pregnancy and menopause and 
searched for associations between premenstrual symptoms 
and postpartum or perimenopausal and either postpartum 
or perimenopausal mood symptoms (or both).49 However, no 
differences were found (Premenstrual-postpartum: p = 0.317; 
Premenstrual-perimenopausal: p = 0.227; Premenstrual 
– either postpartum or perimenopausal mood symptoms: 
p = 0.847; Premenstrual – both: p = 0.288).49
Payne et al. observed an association between a depres-
sive state at the time of the interview and a report of 
premenstrual symptoms in a sample of 665 BD-I patients 
(BD-I depressed at interview: 34.8%, BD-I not depressed 
at interview: 26.4%, p = 0.04).49 However, in another study 
the rate of depression between PMS+ and PMS- patients and 
concluded that being depressed can affect PMS reporting 
(p = 0.56).50 The history of pregnancy among BD-I patients 
with and without PMS was the same [BDI PMS+ (n = 231) 
= 82.8% vs. BDI PMS- (n = 119) = 76.28%, p = 0.1292].50
In addition, Gregory et al. analyzed patients’ moods at 
four different reproductive cycle events (i.e., premenstrual, 
taking oral contraceptives, postpartum and perimenopausal) 
and concluded that women with severe depression at two 
or more of these time points were more likely to have BD 
(p = 0.02).53 The higher prevalence of bipolar depression dur-
ing different phases of the reproductive cycle reinforces the 
54 
Therefore, whenever a patient has depression related to 
the menstrual cycle, BD should be a differential diagnosis.
Illness Course 
Choi et al. combined BD-I and BD-II patients into one patient 
group and searched for an association between seasonality 
and “moderate to severe PMS”.45 They found that the asso-
ciation of both was stronger in the patient group compared 
to the control group (healthy females without psychiatric 
illness) (p = 0.029) and suggested that a common biological 
mechanism of these two cyclic conditions may be involved 
in the development of BD cyclicity.45 However, Fornaro 
and Perugi found similar seasonal patterns in a sample with 
BD-I and BD-II with regard to PMDD (PMDD+ 36.0% vs. PMDD-: 
39.4%, p = ns).48 Both studies present methodological prob-
lems because they have small samples and did not include a 
calendar method or hormone estimation. The measurements 
were based on self-reporting and retrospective evaluation, 
which is prone to bias. This may explain the disparate re-
sults. These methodological limitations reduce the validity 
of the studies.
Figure 1
serotonin activity in predisposed women.
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Dias et al. compared the frequency of mood episodes 
between 191 women with premenstrual exacerbation (PME) 
of BD and 102 women without, all at a premenopausal age.55 
 
(p = 0.02) compared to the other group, but they experienced 
mainly depressive symptoms (p < 0.001, 95% CI-NI).55 Moreover, 
among 66 women with premenstrual exacerbation and 63 with-
out exacerbation who were in a recovery state at baseline, they 
observed a greater risk for relapse in the PME group (p = 0.04).55 
PME may be a marker for a more recurrent and symptomatic 
course of illness among premenopausal women with BD.55
Complaints about premenstrual symptoms were re-
searched by Karadag et al., who found that control subjects 
with no history of medical/mental disorder complained 
than the euthymic BD women (p < 0.05, 95% CI-NI).56 Control 
subjects experienced more menstrual-related mood and 
behavioral changes compared to women with treatment-
responsive BD in both retrospective and prospective assess-
ments.56
groups were observed with respect to vegetative symptoms 
(e.g., somatic complaints, change in appetite and sleep dis-
turbances).56 Karadag et al. concluded that, in euthymic BD 
women, mood-stabilizer treatment might have a prophylactic 
effect against premenstrual symptoms.56
Concerning premenstrual symptoms, Blehar et al. noted 
that 75% (76/101) of women with BD-I described them pri-
marily as increased irritability, anger outbursts and mood 
lability, whereas 25% (24/101) reported their chief symptom 
to be depression.51
The prevalence of rapid cycling did not show any differ-
ences between the two groups retrospectively studied by 
Fornaro and Perugi (PMDD+: 24.0% vs. PMDD-: 26.9%, p = ns) 
and prospectively studied by Dias et al. (PME+: 2.0% vs. PME-: 
2.1%).48,55 However, retrospectively, the group with PMS was 
more likely to report rapid cycling (PME+: 28.8% vs. PME-: 
difference in the rates of psychotic features (PMDD+: 8.0% 
vs. PMDD-: 20.9%, p = ns).48
Differences in personality and transient clinical syn-
dromes (such as hypomania) during the menstrual phases 
were evaluated in 15 LLPDD+ (a disorder very similar to PMDD) 
women and 15 controls.57 The LLPDD+ subjects scored higher 
on measures of hypomania at all menstrual cycle phases 
(p < 0.03, 95% CI-NI).57 The high-scoring subjects in these 
items are evidence of periods of elevated, unstable moods, 
overactivity and destructibility, impulsiveness, and irritabil-
-
abilities of LLPDD patients for affective clinical syndromes.57
Most of these studies found differences between BD 
patients with PMS/PMDD and controls on evaluated crite-
ria. However, the samples are small and each criterion was 
evaluated by only a few studies. Further studies with larger 
samples and rigorous methodologies are required.
Family morbidity
We conducted a family analysis for premenstrual mood symp-
toms in 196 families of BD-I patients.50 The overall rate of 
symptoms was only marginally higher in those with a positive 
family history of premenstrual symptoms compared to those 
with a negative BD history (65.0% vs. 62.1%).50 This difference 
50
Sociodemographic characteristics
Sociodemographic characteristics did not show any difference 
among BD women with or without PMS/PMDD.
Age at onset / age at interview
In one study with 665 BD-I women, the difference in the age 
(mean age = 18.3) and without (mean age = 21.3) PMS (50). 
The same study also found differences in age at the time of 
the interview between both groups (mean age: PMS+ = 41 
vs. PMS- = 45, p = 0.0002).50
However, another study compared 92 female outpatients 
-
cant variation in the mean age at onset of mood disorders 
in PMDD+ versus PMDD- women (24.2 years vs. 23.9 years, 
p = ns).48 Additionally, they did not report difference in 
the mean age at the time of evaluation between these 
groups (mean age: PMDD+= 49.6 years vs. PMDD-= 49.1 years, 
p = ns).48 
The difference in the results most likely occurred because 
while the second evaluated a smaller sample with BD-I and 
BD-II with PMDD.
Marital status
Payne et al. reported no difference in marriage preva-
lence between BD-I patients with or without PMS (50.90% 
vs. 41.03%, respectively, p=0.06) (50). Consistent with 
this finding, Fornaro and Perugi found no difference in 
marital status between patients with BD-I and BD-II who 
were either inpatients or outpatients, with or without 
PMDD.48 The rates for these patients were as follows: 
‘‘never married’’ PMDD+: 12% vs. PMDD-: 27.7%, ‘‘mar-
ried’’ PMDD+: 52% vs. PMDD-: 35.4% and ‘‘widowed or 
divorced’’ PMDD+: 36% vs. PMDD-: 37% (p = ns).48
Presence of Depression at interview
Payne et al. investigated depression at the time of the inter-
view and found that this rate did not differ between women 
with and without premenstrual mood symptoms.50 The num-
ber of major depressive episodes in BD-I patients with PMS 
BD-I patients without PMS (mean = 20.17, p = 0.90) regarding 
the number of manias (mean = 25.55 vs. 15.61, respectively, 
p = 0.1374).50 Payne also found no difference when comparing 
the duration of the longest major depressive episode in 
BD-I patients with (mean = 50.52 weeks) and without 
(mean = 54.11 weeks, p = 0.64) PMS.50
Educational status
Regarding the years of education, neither Payne et al., 
Parry et al., nor Fornaro and Perugi found any differences 
between the two groups.48,50,57 Payne evaluated BD-I patients 
with (mean years of education = 14.45) or without (mean years 
of education = 14.39, p = 0.83) PMS.50 In addition, Fornaro 
and Perugi reported that 52.0% of PMDD+ versus 37.3% of 
PMDD- had 8 years or less of education; 40.0% versus 40.3% 
reported high school-level education, respectively, and 8.0% 
versus 22.3% reported a university-level education (p = ns).48 
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Parry et al. also found no difference in the number of years 
of education (x = 15 ± 0.4, range 12-18 years) between the 15 
people of the control group and the 15 patients with LLPDD. 
Both were free of psychoactive medication and hormonal 
contraceptives.57 
Scale evaluation
McMillan et al. evaluated mood in 16 euthymic patients with 
mood disorders, of which only four were bipolar.58 None of the 
according to the Daily Rating Scale (DRS),59 the Multiple Affect 
Adjective Checklist (MAACL) and the Hamilton Rating Scale 
(HRS).60
a different phenomenon from clinical depression.58
Choi et al. sought to determine whether PMS affected the 
Global Seasonality Score (GSS) of patients with BD-I, BD-II and 
controls, but they found no interaction using the 3 groups 
(p = 0.112).45 Analyzing the association between seasonality 
with “moderate to severe PMS” compared to those without 
this condition (p < 0.0001, 95% CI-NI).45
Karadag et al. compared the Premenstrual Assessment 
Form (PAF) scores of women with treatment-responsive BD 
and control subjects.56 Interestingly, controls experienced 
more premenstrual symptom changes for the sub-groups 
of the PAF corresponding to low mood/loss of pleasure, af-
fective lability, atypical depressive features, “hysteroid” 
features, hostility/anger, anxiety, impulsivity, organic 
mental features, sign of water retention, and impaired social 
functioning compared to the BD group.56 They found no dif-
ference in the scores of other PAF items.56
Karadag et al. applied the Daily Record of Severity of 
Problems-Short Form (DRSP) in 34 euthymic treatment-
responsive BD females and 35 controls with no medical/
mental disorder to evaluate premenstrual and postmenstrual 
symptoms.56
and behavior during two consecutive menstrual cycles than 
control subjects.56 No differences in the vegetative symp-
toms were observed between the two groups.56 It is worth 
remembering that this is a small sample. The hypotheses 
that lithium and/or valproate could be a protective factor 
for PMS in BD patients are controversial.56 One explanation 
would be that BD women could not recognize the more 
subtle variations related to the menstrual cycle because 
illness.56
 
for the following DRSP items: depressed mood, anxiety (dur-
ing the second month), mood swings, anhedonia (during the 
-
trol” feelings.56
the following DRSP items between the BD and control groups: 
anger/irritability, lack of energy, changes in appetite, and 
sleep disturbances.56
Hormonal Rates
Progesterone is metabolized in the ovaries and the brain 
to form the potent neuroactive steroids allopregnanolone 
and pregnenolone, which are positive allosteric modulators 
of the type A GABA neurotransmitter system in the brain.61 
Imaging studies have reported altered GABAergic function 
in women with PMDD when compared with healthy control 
subjects.62,63
allopregnanolone in women with PMDD,64,65 although other 
studies showed no relation.66,67 Failure to demonstrate a sig-
does not necessarily detract from the importance of these 
steroids in the pathogenesis of PMDD because a dissociation 
between peripheral and brain levels of allopregnanolone 
has been demonstrated in rodents.68 Women with PMS dem-
onstrate decreased pregnenolone responsiveness possibly 
due to altered sensitivity of GABA-A receptors.69
Whereas acute, short-term allopregnanolone exposure 
decreases anxiety, chronic exposure to elevated allopreg-
nanolone can produce decreased expression and binding to 
the GABA-A receptor as well as uncoupling of the receptor 
from several anxiolytic modulators, leading to increased 
anxiety.70,71 Progesterone metabolite effects on mood and 
behavior also appear to be biphasic in nature.64 In high 
concentrations, pregnanolone and allopregnanolone pro-
duce anxiolytic, sedative, antiepileptic, and anesthetic ef-
fects.28,72,73 At lower blood levels, similar to those observed 
during the luteal phase, allopregnanolone can cause anxiety, 
aggression, impulsive behavior, and negative mood in pre-
disposed individuals.29,38 While higher doses, similar to those 
observed in late pregnancy, are noted to improve mood.74
deoxycorticosterone,75 which also increases in the brain 
in response to stress via the blood brain barrier.76 It is a 
barbiturate-like ligand of the GABA-A receptor with a com-
mon mechanism of action with allopregnanolone. Steroid 
hormones may modulate the excitability of hypothalamic 
neurons by genomic and non-genomic mechanisms, which 
in turn might be involved in controlling the activity of the 
HPA axis.76
Hardoy et al. evaluated 17 women with BD (4 BD-I and 
13 BD-II), 14 women with MDD and 16 healthy control sub-
jects).47 All patients were euthymic for three months. This 
study examined plasma concentrations of the steroids cor-
47 
Hardoy et al. found that the concentrations of proges-
the 3 groups of subjects (progesterone: BD = 11.0 ± 2.6, 
MDD = 4.0 ± 3.6, controls = 1.0 ± 1.1, p < 0.0001, 95% CI-NI; 
allopregnanolone: BD = 9.6 ± 2.3, MDD = 5.1 ± 1.2, controls 
= 2.1 ± 0.8, p < 0.0001, 95% CI-NI).47 Furthermore, the con-
centrations of these steroids were even greater in women 
with BD than in those affected by MDD.47 No differences 
these comparisons.47
The same study found higher concentrations of proges-
modulator of GABA, in euthymic BD patients with and 
without PMDD.47 However, these patients were euthymic for 
at least 3 months, so these results cannot be compared to 
previous studies. Women with a lifetime diagnosis of mood 
disorder (BD or MDD) but who are currently in a condition 
of clinical well-being exhibited higher plasma concentra-
-
teal phase of the menstrual cycle than healthy controls.47 
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It is unclear why those women lost the inhibition of proges-
terone release. Thus, high levels of progesterone and its 
metabolite in the luteal phase is a possible biological marker 
for mood disorders in women.
A bias due to medication or comorbidity was evalu-
ated.47 Drug-free patients with BD or MDD showed similar 
differences in steroid concentrations relative to controls 
as drug-treated patients.47 However, only 8 patients were 
drug-free, corresponding to 2 BD (11.8%) and 6 MDD (42.8%) 
patients.47 Patients affected by mood disorders (BD or MDD) 
but without comorbidity for Panic Disorder (PD), Obsessive-
compulsive Disorder (OCD), or Eating Disorder (ED) had 
higher plasma levels of progesterone and allopregnano-
lone compared to controls, which was similar to patients 
with comorbidity for either of these conditions.47 Therefore, 
the differences in neuroactive steroid concentrations 
were not attributable to comorbidity with PD, OCD, or ED. 
Comparing the concentrations of progesterone and allopreg-
nanolone between subjects with PMDD and those without it 
47
Treatment Response 
Jacobsen compared “anticycling” mood stabilizer responses 
to valproate between rapidly cycling women with (N = 11) 
and without (N = 5) PMS.77 These study tested low-dose val-
proate as a treatment for cyclothymia, rapid cycling BD-II 
and PMS.77 However, he found that patients with primary PMS 
had less sustained responses78 to valproate than cyclothymic 
or BD-II patients with secondary PMS. Only three of eight 
(38%) women with PMS reported a good response to low-dose 
patients needed high-dose valproate treatments.77 It is worth 
noting that these results may be due to the small sample size.
which would increase 5HT activity, so it is possible that some 
women with PMS might improve. Reports from human and 
animal studies indicate that eventually all GABA-A receptor 
agonists can induce symptoms similar to depressed mood, 
anxiety, irritability, aggression, and other typical symptoms 
of PMS/PMDD.77 GABA-A receptor agonists at high doses 
are anxiolytic, anti-aggressive, sedative/anesthetic, and 
anti-epileptic.79 However, in low concentrations or doses, 
there are severe adverse emotional reactions in a subset of 
individuals (2-3%) and moderate reactions are seen in up to 
20% of patients.80 
It is also important to note that valproate can induce 
polycystic ovary syndrome and could interfere with nor-
whether menstrual dysfunction is secondary to psychotropic 
medication use or related to BD.81,82 Nevertheless BD females 
that improve with valproate take advantage not only from 
improved mood stability but also can enhance premenstrual 
symptoms.56
Case reports and Case series
Hsiao and Liu wrote two case reports about BD and PMS 
comorbidity.83 They made a prospective evaluation with a se-
ries of laboratory tests (which involved testing for the levels 
of hemoglobin, thyroid-stimulating hormone, fasting glucose, 
estradiol, progesterone, prolactin, and follicle-stimulating 
hormone) and scales.
manic episodes from 2–3 days before menstruation until 
the second day after menstruation began for the previous 
two years. She was treated with premenstrual doses of an 
antipsychotic medication.83
The other case is a 34-year-old woman with a single 
manic episode at postpartum onset. The patient developed 
psychotic symptoms one week before almost every menstrual 
period, with full remission observed 3-4 days after the onset 
of menstruation.83 The mood stabilizer and the antipsychotic 
doses were increased during the luteal phase. After three 
months, the severity of psychotic symptoms decreased, 
and the PRISM severity score (PSS) decreased from 88% to 
17%. One year later, her premenstrual psychotic symptoms 
remained, but they did not disturb the quality of her life.83
Becker et al. reported a case about a 43-year-old woman 
with a 30-year history of treatment-resistant menstrually re-
lated rapid cycling bipolar disorder.78 This patient had failed 
to respond to or tolerate all previous medication. Lamotrigine 
was increased gradually, and the mood cycle amplitude at-
tenuated. There was a notable decrease in the severity and 
follicular phase of the menstrual cycle.
In the six months prior to initiating LTG, the patient re-
corded mood and physiological premenstrual symptoms on 
the Endicott Premenstrual Assessment Form.84 In the luteal 
phase compared with the follicular phase, the mean depres-
sive symptoms were 67% (range: 39-96) lower, the mean joy 
the mean work impairment score dropped by 63% (range: 
26-108) (i.e., she experienced improved work function). Her 
medications at the time of the evaluation included divalproex 
mg/day and levothyroxine 175 lg/day (serum TSH 1.9 lIU/mL) 
as LTG increased until a dose of 300 mg was attained and 
maintained with good adherence.
Lamotrigine might be able to treat pathological entrain-
this patient with LTG could be related to its robust actions 
against the depressive aspects of bipolar disorders and its 
lack of a tendency to cause sedation.85 The hypothesis that 
certain antiglutamatergic agents, such as LTG, may offer 
more robust antidepressant actions and less sedation while 
certain GABAergic agents, such as valproate, may provide 
more robust antimanic actions and more sedation86 warrants 
systematic investigation. This patient not only achieved 
euthymia without the use of antidepressants, but she also 
exhibited a clear attenuation of a longstanding relationship 
between mood and the menstrual cycle.
D'Mello et al. reported two cases of premenstrual mania.87 
-
strual mania. She was treated with lithium and thiothixene 
and maintained only with lithium (1,800 mg/day - serum 
level = 0.9 mEq/L). The second case describes a 41-year-old 
woman who had a major depressive episode 4 years before 
and since then had experienced premenstrual mixed mania 
according to the DSM-III with a stable mood between menses. 
She was treated with lithium 900 mg/day with serum levels 
in the 0.6 to 0.8 mEq/L range. She remained stabilized after 
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levels were observed during the menstrual phases in both 
cases. In both cases, lithium therapy interrupted the recur-
rent premenstrual mood symptoms.
D'Mello et al. reports the importance of investigating 
the interface between LLPDD and BD.87 Case reports have 
little value in the hierarchy of evidence, but clinicians 
may understand the importance of diagnosing and treat-
ing this comorbidity.
Discussion
To the best of our knowledge, no systematic reviews have 
examined the comorbidity of BD and PMS/PMDD. The present 
work aimed at reviewing the comorbidity of PMS or PMDD and 
BD, identifying the variables that require further investiga-
tion and reminding physicians that special care is required 
for diagnosis and therapy. 
-
ric and psychological aspects because their clinical features 
gonadal hormones and neurotransmitters sensibility. 
The studies analyzed suggest increased risks among 
women either the PMS or PMDD for BD-I or BD-II and a greater 
risk of women with BD-II of having PMS or PMDD. Furthermore, 
women with BD and PMS report increased mood lability, an-
ger, irritability, severe symptoms and frequent relapses of 
their BD illness and a worse therapeutic response. Insomnia 
is common in PMS,88 and sleep deprivation may induce or 
perpetuate mania in BD patients.89 These symptoms might 
be one of the factors that explain the higher intensity of 
manic episodes and longer subsyndromal episodes in bipolar 
women with PMS.55
Future research should attempt to stabilize hormonal 
levels with continuous use of contraceptives or naturally, 
as in gestation and menopause, to see if this causes a reduc-
tion in the severity of illness. In addition, psychiatrists should 
note menstrual period dates and compare symptom intensity 
between the luteal and follicular phases. Further character-
ization of the role of neuroactive steroids in mood disorders 
may lead to the development of new therapeutic approaches.
Several human studies have suggested an estrogen-
serotonin hypothesis.90 Estrogen decrease might increase 
MAO and reduce 5HT receptor sensitivity, which may lead 
to depression in susceptible women.90 
This review demonstrates the importance of diagnosing 
PMS/PMDD comorbidity, the worse course of disease, the 
higher number of coexisting psychiatric diseases and 
the need for a consensus about the PMS/PMDD criteria 
and the evaluation tools. Still, BD and PMS/PMDD should 
be further investigated because a lack of research exists. 
Furthermore, there were also some methodological limi-
tations in this review: the studies used different criteria 
to diagnose PMS. Retrospective diagnoses of PMDD and 
generalizations from the data were not allowed because 
of the small samples.
Conclusion
This overview points to an established correlation be-
tween BD and PMS/PMDD. Nevertheless, this is still an 
under-studied topic. On the other hand, some reports have 
demonstrated the absence of a relationship between BD and 
the menstrual cycle phases, which emphasizes that research 
should be conducted with PMS/PMDD patients separately.
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